目的 建立二甲雙胍藥物利用評(píng)價(jià)標(biāo)準(zhǔn)，評(píng)價(jià)臨床使用的合理性。方法 以鹽酸二甲雙胍片和鹽酸二甲雙胍緩釋片藥品說(shuō)明書為基礎(chǔ)，參考相關(guān)指南和專家共識(shí)，建立評(píng)價(jià)標(biāo)準(zhǔn)。利用AHP加權(quán)TOPSIS法評(píng)價(jià)醫(yī)院2023年1月～12月242份病例二甲雙胍使用的合理性。結(jié)果 242份病例中，74份使用合理（占比30.58%）；153份使用基本合理（占比63.22%）；15份使用不合理（占比6.20%）。結(jié)論 建立的二甲雙胍藥物利用評(píng)價(jià)標(biāo)準(zhǔn)和AHP加權(quán)TOPSIS法可用于二甲雙胍的合理性評(píng)價(jià)，評(píng)價(jià)結(jié)果顯示該藥的使用基本合理。

Objective To establish the evaluation criteria of metformin drug utilization and evaluate the rationality of clinical use. Methods Based on the drug instructions of Metformin Hydrochloride Tablets and Metformin Hydrochloride Sustained-release Tablets, the evaluation criteria were established with reference to relevant guidelines and expert consensus. The rationality of using metformin in 242 patients in January to December 2023 was evaluated by AHP weighted TOPSIS method. Results Among 242 cases, metformin was used reasonably in 74 cases (30.58%). The use of metformin was reasonable in 153 cases (63.22%). The use of metformin was unreasonable in 15 cases (6.20%). Conclusion The established evaluation criteria and AHP weighted TOPSIS method can be used to evaluate the rationality of metformin, and the evaluation results show that the use of metformin is basically reasonable.

R977

安徽省衛(wèi)生健康科研項(xiàng)目（AHWJ2023BAc10045）